Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

22
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
22

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epidermal Growth Factor Receptor Inhibitor Use and Postoperative Outcomes Following Mohs Micrographic Surgery.

International journal of dermatologyĀ·2026
Same author

IGF1 modulates lesional skin inflammation in checkpoint inhibitor-induced lichen planus.

bioRxiv : the preprint server for biologyĀ·2026
Same author

Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial.

Journal of clinical oncology : official journal of the American Society of Clinical OncologyĀ·2026
Same author

KIM-1 and Circulating Tumor DNA Are Prognostic Markers for Oligometastatic Clear-cell Renal Cell Carcinoma: Development of a Multivariable Prognostic Model.

European urologyĀ·2026
Same author

Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele.

CancerĀ·2026
Same author

Postoperative Outcomes in Dermatologic Surgery Among Patients Receiving VEGF and VEGFR Inhibitors: A Propensity-Matched Real-World Analysis.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]Ā·2026

Related Experiment Video

Updated: Sep 4, 2025

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.4K

Periorbital edema associated with alpelisib.

Elizabeth A Dao1, Saira J George2, Meghan M Heberton3

  • 1Louisiana State University Health Sciences Center School of Medicine, 2020 Gravier St., New Orleans, LA 70112, USA.

Cancer Treatment and Research Communications
|July 14, 2022
PubMed
Summary

Alpelisib, a PI3K inhibitor for breast cancer, can cause rare periorbital edema. Early dermatology consultation is key for managing this unique cutaneous side effect.

Keywords:
AlpelisibBreast cancerCutaneous adverse eventsDermatologyPhosphatidylinositol 3-kinase inhibitors

More Related Videos

Iris Fixation via External Pentagram Suturing
05:22

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

1.4K
A Rabbit Model of Aqueous-Deficient Dry Eye Disease Induced by Concanavalin A Injection into the Lacrimal Glands: Application to Drug Efficacy Studies
08:04

A Rabbit Model of Aqueous-Deficient Dry Eye Disease Induced by Concanavalin A Injection into the Lacrimal Glands: Application to Drug Efficacy Studies

Published on: January 24, 2020

12.5K

Related Experiment Videos

Last Updated: Sep 4, 2025

Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.4K
Iris Fixation via External Pentagram Suturing
05:22

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

1.4K
A Rabbit Model of Aqueous-Deficient Dry Eye Disease Induced by Concanavalin A Injection into the Lacrimal Glands: Application to Drug Efficacy Studies
08:04

A Rabbit Model of Aqueous-Deficient Dry Eye Disease Induced by Concanavalin A Injection into the Lacrimal Glands: Application to Drug Efficacy Studies

Published on: January 24, 2020

12.5K

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Alpelisib targets PI3K for HR+/HER2- metastatic breast cancer.
  • Common alpelisib side effects include hyperglycemia, rash, and GI upset.
  • Morbilliform rash is a typical cutaneous reaction to alpelisib.

Purpose of the Study:

  • To report two cases of periorbital edema associated with alpelisib.
  • To discuss the clinical presentation, management, and prognosis of this adverse event.
  • To emphasize the role of dermatology in managing alpelisib-induced cutaneous reactions.

Main Methods:

  • Case report of two patients experiencing periorbital edema.
  • Clinical data collection and review.
  • Literature review on alpelisib adverse events.

Main Results:

  • Two patients developed periorbital edema while on alpelisib therapy.
  • The reaction was managed effectively with dermatological intervention.
  • Periorbital edema represents a distinct cutaneous adverse event of alpelisib.

Conclusions:

  • Periorbital edema is a rare but notable adverse event of alpelisib.
  • Prompt dermatological assessment and management are crucial for patients experiencing this reaction.
  • Understanding unique alpelisib-induced skin toxicities improves patient care.